Deborah U Waters, MD | |
Us Hwy 491 North, Shiprock, NM 87420 | |
(505) 368-6300 | |
(505) 368-6324 |
Full Name | Deborah U Waters |
---|---|
Gender | Female |
Speciality | Physical Medicine & Rehabilitation - Sports Medicine |
Location | Us Hwy 491 North, Shiprock, New Mexico |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073502639 | NPI | - | NPPES |
43280579 | Medicaid | CO | |
432394 | Medicaid | AZ | |
Q9896 | Medicaid | NM |
Entity Name | Dhhs Phs Naihs Shiprock Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780639971 PECOS PAC ID: 0749193837 Enrollment ID: O20031105000809 |
News Archive
Obesity causes an increase in the stiffness of the heart, making it hard for the heart muscle to relax and fill with blood in between heartbeats. This abnormal stiffness can lead to congestive heart failure and other problems as it becomes more severe.
Kaiser Health News staff writer Christopher Weaver, working in collaboration with USA Today, reports: "At the Cypress Pointe Surgical Hospital here, construction workers scrambled on a recent day to turn a mud pit into a parking lot and put other finishing touches on the $35 million physician-owned facility" (Weaver, 10/28).
Gastric bypass patients who attended five follow-up office visits in two years as recommended by their surgeons lost nearly twice as much weight (113 lbs. vs. 57 lbs.) as patients who attended only two follow-up visits, according to a University of Pennsylvania School of Nursing study in Obesity Surgery.
Critical Path Institute's Patient-Reported Outcome Consortium announces its first clinical outcome assessment qualification from the US Food and Drug Administration for the Symptoms of Major Depressive Disorder Scale.
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Deborah U Waters, MD Po Box 160, Shiprock, NM 87420-0160 Ph: (505) 368-6300 | Deborah U Waters, MD Us Hwy 491 North, Shiprock, NM 87420 Ph: (505) 368-6300 |
News Archive
Obesity causes an increase in the stiffness of the heart, making it hard for the heart muscle to relax and fill with blood in between heartbeats. This abnormal stiffness can lead to congestive heart failure and other problems as it becomes more severe.
Kaiser Health News staff writer Christopher Weaver, working in collaboration with USA Today, reports: "At the Cypress Pointe Surgical Hospital here, construction workers scrambled on a recent day to turn a mud pit into a parking lot and put other finishing touches on the $35 million physician-owned facility" (Weaver, 10/28).
Gastric bypass patients who attended five follow-up office visits in two years as recommended by their surgeons lost nearly twice as much weight (113 lbs. vs. 57 lbs.) as patients who attended only two follow-up visits, according to a University of Pennsylvania School of Nursing study in Obesity Surgery.
Critical Path Institute's Patient-Reported Outcome Consortium announces its first clinical outcome assessment qualification from the US Food and Drug Administration for the Symptoms of Major Depressive Disorder Scale.
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
› Verified 5 days ago